Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Deferred Tax Liability (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Non-Current Deferred Tax Liability for 6 consecutive years, with $548000.0 as the latest value for Q3 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 1.62% to $548000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $548000.0 through Sep 2025, down 1.62% year-over-year, with the annual reading at $548000.0 for FY2024, 1.62% down from the prior year.
  • Non-Current Deferred Tax Liability for Q3 2025 was $548000.0 at Caribou Biosciences, roughly flat from $548000.0 in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $10.9 million in Q4 2022, with the low at $155000.0 in Q2 2021.
  • Average Non-Current Deferred Tax Liability over 5 years is $1.0 million, with a median of $512000.0 recorded in 2021.
  • The sharpest move saw Non-Current Deferred Tax Liability soared 2186.55% in 2022, then crashed 94.88% in 2023.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $476000.0 in 2021, then skyrocketed by 2186.55% to $10.9 million in 2022, then plummeted by 94.88% to $557000.0 in 2023, then decreased by 1.62% to $548000.0 in 2024, then changed by 0.0% to $548000.0 in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $548000.0, $548000.0, and $548000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.